tiprankstipranks
Advertisement
Advertisement

HK:2696 Stock Latest News

Henlius Wins China Approval for New Gastric Cancer Use of HANSIZHUANG
Company AnnouncementsHenlius Wins China Approval for New Gastric Cancer Use of HANSIZHUANG
5d ago
2696
Henlius Starts Global Phase 1 Trial of Pembrolizumab Biosimilar HLX17 in U.S. and China
PremiumCompany Announcements
Henlius Starts Global Phase 1 Trial of Pembrolizumab Biosimilar HLX17 in U.S. and China
9d ago
2696
Henlius Wins China Approval for HANBEIYOU Breast Cancer Biosimilar
PremiumCompany Announcements
Henlius Wins China Approval for HANBEIYOU Breast Cancer Biosimilar
16d ago
2696
Henlius Starts Global Phase 2/3 Trial of ADC HLX43 in Advanced Lung Cancer
PremiumCompany Announcements
Henlius Starts Global Phase 2/3 Trial of ADC HLX43 in Advanced Lung Cancer
17d ago
2696
Henlius Starts First-Patient Dosing in Phase 1 Study of Daratumumab Biosimilar HLX15-SC for Newly Diagnosed Multiple Myeloma
PremiumCompany Announcements
Henlius Starts First-Patient Dosing in Phase 1 Study of Daratumumab Biosimilar HLX15-SC for Newly Diagnosed Multiple Myeloma
19d ago
2696
Henlius doses first patient in pivotal HLX07–serplulimab lung cancer trial in China
PremiumCompany AnnouncementsHenlius doses first patient in pivotal HLX07–serplulimab lung cancer trial in China
19d ago
2696
Henlius Wins Key EMA Backing for Serplulimab Lung Cancer Use
Premium
Company Announcements
Henlius Wins Key EMA Backing for Serplulimab Lung Cancer Use
23d ago
2696
Henlius Begins First-in-Human Trial of First-in-Class B7-H3 Cancer Fusion Protein
Premium
Company Announcements
Henlius Begins First-in-Human Trial of First-in-Class B7-H3 Cancer Fusion Protein
23d ago
2696
Henlius Wins NMPA Nod for First-in-Human Trial of Bispecific ADC HLX48
PremiumCompany Announcements
Henlius Wins NMPA Nod for First-in-Human Trial of Bispecific ADC HLX48
24d ago
2696
Henlius Wins Australian Nod to Start First-in-Class Trispecific Antibody Trial for Advanced Prostate Cancer
PremiumCompany Announcements
Henlius Wins Australian Nod to Start First-in-Class Trispecific Antibody Trial for Advanced Prostate Cancer
24d ago
2696
Henlius Doses First EU Patient in Global Phase 2 Trial of HLX43 for Advanced Lung Cancer
PremiumCompany Announcements
Henlius Doses First EU Patient in Global Phase 2 Trial of HLX43 for Advanced Lung Cancer
24d ago
2696
Henlius Shareholders Unanimously Approve 2025 Reports and Profit Distribution
PremiumCompany Announcements
Henlius Shareholders Unanimously Approve 2025 Reports and Profit Distribution
26d ago
2696
Henlius Wins Australian Nod for First-in-Class Bispecific Cancer ADC Trial
PremiumCompany AnnouncementsHenlius Wins Australian Nod for First-in-Class Bispecific Cancer ADC Trial
1M ago
2696
Henlius Starts First-in-Human Trial of Novel KAT6A/B Inhibitor HLX97 in Advanced Tumours
Premium
Company Announcements
Henlius Starts First-in-Human Trial of Novel KAT6A/B Inhibitor HLX97 in Advanced Tumours
1M ago
2696
Henlius Wins EU Approval for Two New Serplulimab Cancer Uses
Premium
Company Announcements
Henlius Wins EU Approval for Two New Serplulimab Cancer Uses
1M ago
2696
Henlius Wins FDA Nod to Begin U.S. Trial of Cetuximab Biosimilar HLX05-N
PremiumCompany Announcements
Henlius Wins FDA Nod to Begin U.S. Trial of Cetuximab Biosimilar HLX05-N
1M ago
2696
Henlius Wins Japan Go-Ahead for Global Phase 2/3 Trial of Lung Cancer ADC HLX43
PremiumCompany Announcements
Henlius Wins Japan Go-Ahead for Global Phase 2/3 Trial of Lung Cancer ADC HLX43
1M ago
2696
Henlius Starts First-in-Human Trial of Novel Tetra-Specific Cancer Antibody HLX3901
PremiumCompany Announcements
Henlius Starts First-in-Human Trial of Novel Tetra-Specific Cancer Antibody HLX3901
2M ago
2696
Henlius Wins EU Nod for Pertuzumab Biosimilar, Expanding Global Oncology Footprint
PremiumCompany Announcements
Henlius Wins EU Nod for Pertuzumab Biosimilar, Expanding Global Oncology Footprint
2M ago
2696
Henlius wins Australian nod for global phase 2/3 trial of HLX07 combo in advanced lung cancer
PremiumCompany AnnouncementsHenlius wins Australian nod for global phase 2/3 trial of HLX07 combo in advanced lung cancer
2M ago
2696
Henlius Sets 2026 AGM to Approve 2025 Results and New Share Issuance Mandate
Premium
Company Announcements
Henlius Sets 2026 AGM to Approve 2025 Results and New Share Issuance Mandate
2M ago
2696
Henlius Grants New Share Options and RSUs to Align Incentives With Performance
Premium
Company Announcements
Henlius Grants New Share Options and RSUs to Align Incentives With Performance
2M ago
2696

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >